Previous 10 | Next 10 |
Gilead Sciences (NASDAQ: GILD) created the antiviral drug Remdesivir as a possible treatment for Ebola and the Marburg virus, and it's since been found to be potentially effective in treating COVID-19, the disease caused by the novel coronavirus. Some investors think this could mean signific...
Behemoth biotech Gilead Sciences (NASDAQ: GILD) announced on March 2 that it will acquire up-and-coming cancer drug developer Forty Seven (NASDAQ: FTSV) for $4.9 billion. Biotech investors had been calling on Gilead to make strategic moves like this to shore up prospects in the wa...
NEW YORK, NY / ACCESSWIRE / March 24, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning t...
NEW YORK, March 24, 2020 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning th...
In our last edition , we mentioned how for the first time in nearly 10 years we saw insider buying outpace selling and wrote the following, We have been tracking insider data for nearly 10 years and in all this time we have not come across a single week where insider buying outpaced ...
Forty Seven (NASDAQ: FTSV ): Q4 GAAP EPS of -$0.61 beats by $0.10 . More news on: Forty Seven, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
-- Presented Updated Data for Magrolimab Showing Robust, Durable Activity in MDS and AML -- -- Presented Foundational Preclinical Data for FSI-174 and Entered into Collaborations with bluebird bio and Rocket Pharmaceuticals to Expand Development Program -- -- Gilead Acquisition of...
NEW YORK, NY / ACCESSWIRE / March 17, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the...
NEW YORK, March 17, 2020 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning th...
By Daniel Shvartsman It's been quite a week, and really quite a 3-week stretch since February 21st. A bear market is here, COVID-19 has infected thousands of people and affected markets and events around the world. There are many fundamental battles out there to be waged and steps to be ta...
News, Short Squeeze, Breakout and More Instantly...
The ongoing COVID-19 pandemic has caused significant disruptions to the global economy, as well as grievances for families witnessing their loved ones die from the virus. Fortunately, there's finally a light at the end of the tunnel as one investigative treatment has revealed potential efficacy ...
For years, Gilead Sciences ' (NASDAQ: GILD) stock price has been rather disappointing for investors hoping for long-term capital appreciation. While shares do boast an impressive 3.63% dividend yield, the company's revenues have experienced an enormous decline from 2015 onwards, falling over ...
Shares of Forty Seven (NASDAQ: FTSV) climbed 64.5% in March, according to data from S&P Global Market Intelligence . The immuno-oncology specialist's stock skyrocketed early in the month after it was announced that the company was on track to be purchased by Gilead Sciences...